Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
Instructions to Pick the Right Dental Embed Trained professional: An Exhaustive Aide- Going on a bad date is a drag. Worse? Ending up as a cautionary tale on TikTok.
- 25 of the world’s best sandwiches
- The Best 20 Photography Instagram Records to Follow
- Anti-war protests held across Israel under wartime gathering limits
- Brazil's agricultural research agency gets cannabis research greenlight
- FBI arrests Brian Cole Jr. in Jan. 6 pipe bomb investigation, ending 5-year hunt
- Cocaine, caffeine, painkillers consumed by sharks in Bahamas, study finds
- Curl Up With Some Hot Chocolate And Watch Mighty Car Mods Explore Japan In A Honda City Turbo II
